Prosecution Insights
Last updated: November 04, 2026
Application No. 17/639,819

OPTICALLY READABLE BARCODES AND SYSTEMS AND METHODS FOR CHARACTERIZING MOLECULAR INTERACTIONS

Final Rejection §103§DOUBLEPATENT
Filed
Mar 02, 2022
Priority
Sep 03, 2019 — provisional 62/895,159 +2 more
Examiner
YOUNG, BRIAN ELLIS
Art Unit
1684
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Flexomics LLC
OA Round
2 (Final)
65%
Grant Probability
Favorable
3-4
OA Rounds
0m
Est. Remaining
86%
With Interview

Examiner Intelligence

Grants 65% — above average
65%
Career Allowance Rate
26 granted / 40 resolved
+5.0% vs TC avg
Strong +21% interview lift
Without
With
+21.4%
Interview Lift
resolved cases with interview
Typical timeline
3y 9m
Avg Prosecution
27 currently pending
Career history
74
Total Applications
across all art units

Statute-Specific Performance

§101
2.4%
-37.6% vs TC avg
§103
35.9%
-4.1% vs TC avg
§102
15.5%
-24.5% vs TC avg
§112
29.0%
-11.0% vs TC avg
Black line = Tech Center average estimate • Based on career data from 40 resolved cases

Office Action

§103 §DOUBLEPATENT
DETAILED ACTION Notice of Pre-AIA or AIA Status 1. The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Election/Restrictions 2. Applicant’s amendments to claims 19-26, filed on 04 August 2026, now incorporate all of the limitations of independent claim 27 and therefore claims 19-26 are rejoined with Group IV, claims 27 and 29-38. Claim Rejections - 35 USC § 103 3. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. 4. Claims 19, 24-27, 29-32, 34, 35 and 68 are rejected under 35 U.S.C. 103 as being unpatentable over Soumillon et al (International Patent Application No. WO 2018064640, published 05 April 2018) in view of Schimak et al (MiL-FISH: Multilabeled Oligonucleotides for Fluorescence In Situ Hybridization Improve Visualization of Bacterial Cells, Applied Environmental Microbiology, 82, 1, published 22 December 2015). Regarding claim 27, Soumillon teaches a solid support detection system comprising a solid support and a plurality of pens (i.e., wells; [00123] and FIG. 1A), a plurality of oligonucleotide-conjugated beads with each bead comprising a bead and a plurality of oligonucleotide complexes conjugated to the bead (FIG. 6 and [00117]). Soumillon teaches that each oligonucleotide complex comprises a primer sequence ([00117]), an optically readable well-identifying barcode comprising (i.e., the barcode is optically readable by the hybridization of fluorescently labeled complementary probes; 3 or more cassetable barcode sequence [00147], hybridization probes [00149], and FIG. 5). Soumillon teaches that each capture probe on a capture object has a different unique molecular identifier (UMI) from other capture probes on the capture object (i.e., a plurality of UMIs; [00139]). Soumillon teaches that the capture sequence on the capture oligonucleotide is a random hexamer (i.e., there is more than one distinct capture sequence on oligonucleotides conjugated to the same bead; [00134]). Soumillon teaches a plurality of wells, each comprising one oligonucleotide bead ([00123]). Soumillon teaches a plurality of fluorescently labeled hybridization probes (i.e., optically readable oligonucleotide probes comprising a second plurality of nucleotide sequences) that are complementary to the cassetable barcode sequences on the bead ([00149]) that the location of each cell barcode is identified via imaging of the hybridization probes and recorded (i.e., mapped; [00498]). Soumillon does not teach that at least one nucleotide sequence of the second plurality of nucleotide sequences carries two or more distinct fluorescent labels, wherein the second plurality of nucleotide sequences is capable of forming a number of uniquely distinguishable fluorescent combinations that exceeds the number of distinct fluorescent labels used to form each fluorescent word. However, Schimak teaches oligonucleotide probes that comprise up to 3 distinct fluorophores (e.g. the Arch915 probe on SI pg. 5, row 1 of SI Table 1, comprising 2 internal Cy5 dyes, a 5' Cy3 dye and a 3' Atto 488 dye). Schimak teaches that this combinatorial labeling approach allows for the detection of 2n-1 targets (i.e., the claimed words of the optically readable well-identifying barcode; pg. 62 column 2 ¶ 1), where n is the number of distinct fluorophores. Therefore, Schimak teaches a plurality of nucleotide sequences that are capable of forming a number of uniquely distinguishable fluorescent combinations that exceeds the number of distinct fluorescent labels used to form the fluorescent word (e.g., the n=3 distinct fluorescent labels taught by Schimak would enable 2n-1, or 15, possible targets). It would have been obvious to one having ordinary skill in the art to have modified the hybridization probes taught by Soumillon with the combinatorial labeling method taught by Schimak to arrive at the instantly claimed invention with a reasonable expectation of success. The ordinary artisan would have been motivated to make this modification because Schimak specifically teaches that multi-labeled probes provide a higher maximum signal and an increased signal to background as compared to single-labeled probes (pg. 66 column 2 ¶ 2), providing potential advantages such as time saving through reduced exposure times or increased accuracy of barcode assignment. In addition, one having ordinary skill in the art would have recognized that the known techniques in the cited references could have been combined with predictable results because the known techniques in the cited references predictably result in the spatial imaging of fluorescent oligonucleotide probes. Regarding claim 29, Soumillon teaches a cell in a well comprising one of the oligonucleotide-conjugated beads ([0007]). Regarding claim 30, Soumillon teaches that the cell is a T cell ([00234] and [00457]). Regarding claim 31, Soumillon teaches T cells stained with antigen (i.e., an interacting molecular component) in individual wells ([00459]). Regarding claim 32, Soumillon teaches that the biological cell in the well is a macrophage (i.e., an antigen presenting cell; [0084], [00234], [00261]). In this embodiment there is a cell in the wells containing one of the oligonucleotide-conjugated beads, the cell is an antigen presenting cell, and the cell is an interacting molecular component (i.e., the cell interacts with the oligonucleotide-conjugated bead). Regarding claim 34, Soumillon teaches performing a protein expression assay (i.e., a functional assay) on a biological cell and observing a detectable signal generated during said assay (FIG. 4B, [00580] and [00581]). Regarding claim 35, Soumillon teaches that the biological micro-object (i.e., the cell) is lysed using a lysing reagent (i.e., a cell lysing agent) in the well ([00637]). Regarding claim 19, Soumillon in view of Schimak teaches optically readable probes comprising 18-20 nucleotides (SI Table 1). Regarding claim 24, Soumillon teaches that the capture sequence on the capture oligonucleotide of a capture object is not the same (i.e., there are different types of capture sequences on an individual capture object; [00144]). Regarding claims 25 and 26, Soumillon teaches capture sequences that comprise polyT sequences ([00144]) or TCR/BCR sequences ([00237]). Regarding claim 68, Schimak teaches a nucleotide probe sequence comprising 3 distinct fluorophores capable of forming 2n-1 unique fluorescent combinations (e.g., if n = 3, then 7 unique combinations; pg. 62 column 2 ¶ 1 and SI Table 1). 5. Claims 20-23 are rejected under 35 U.S.C. 103 as being unpatentable over Soumillon et al (International Patent Application No. WO 2018064640, published 05 April 2018) in view of Schimak et al (MiL-FISH: Multilabeled Oligonucleotides for Fluorescence In Situ Hybridization Improve Visualization of Bacterial Cells, Applied Environmental Microbiology, 82, 1, published 22 December 2015) as applied to claim 27 above, and further in view of Cekan et al (International Patent Application No. WO 2020070325, with valid priority to 05 October 2018). Regarding claims 20-23, the solid support detection system of claim 27 is discussed fully above and incorporated here. Schimak teaches an optically readable oligonucleotide probe comprising 4 fluorophores (however, only 3 distinct fluorophores; SI Table 1). Schimak additionally teaches that their probes of 18-20 nucleotides can be labeled with “at least twice the number of labels” (i.e., at least 8 fluorophores; pg. 66 column 2 ¶ 3). Neither Soumillon nor Schimak specifically teaches 4, 5, 6 or 7 distinct fluorophores on the optically readable probe. However, Cekan teaches the simultaneous detection of 7 distinct fluorophores (FIG 3 and pg. 15 lines 15-20). It would have been obvious to one having ordinary skill in the art to have modified the optically readable probe taught by Soumillon in view of Schimak to have incorporated up to at least 8 fluorophores, as specifically taught by Schimak (pg. 66 column 2 ¶ 3), and to have at least 7 of those fluorophores be spectrally distinct fluorophores as taught by Cekan, to arrive at the instantly claimed invention with a reasonable expectation of success. The ordinary artisan would have been motivated to increase the number of distinct fluorophores in order to combinatorially increase the number of possible targets (i.e., words) as taught by Schimak (e.g., at 7 distinct fluorophores as disclosed by Cekan, Schimak teaches that there are 2n-1 possible targets, or 127 possible words). In addition, the ordinary artisan would have recognized that the known techniques in the cited references could have been combined with predictable results because the known techniques in the cited references predictably result in the imaging of multiply-labeled oligonucleotide probes. 6. Claim 33 is rejected under 35 U.S.C. 103 as being unpatentable over Soumillon et al (International Patent Application No. WO 2018064640, published 05 April 2018) in view of Schimak et al (MiL-FISH: Multilabeled Oligonucleotides for Fluorescence In Situ Hybridization Improve Visualization of Bacterial Cells, Applied Environmental Microbiology, 82, 1, published 22 December 2015) as applied to claim 31 above, and further in view of Correa et al (Evaluation of antigen-conjugated fluorescent beads to identify antigen-specific B cells, Frontiers in Immunology, 9, 493, 1-17, published 23 March 2018). Regarding claim 33, the method of claim 31 is discussed fully above and incorporated here. Soumillon further teaches that each pen (i.e., well) comprises a plurality of micro-objects ([00365]) and that micro-objects are antigen coated beads (beads with covalently attached antigens; [0083]) or B cells ([00372]), but Soumillon does not specifically teach an embodiment wherein a well comprises a cell and an antigen-coated bead with the capture object (i.e., the oligonucleotide-conjugated bead). However, Correa teaches an assay for the identification of antigen-specific monoclonal antibodies wherein antigen-coated beads are mixed with B-cells and then sequenced to identify variable regions (FIGURE 1). It would have been obvious to one having ordinary skill in the art to have modified the method taught by Soumillon such that antigen-coated beads were sequestered with B-cells as taught by Correa to arrive at the instantly claimed invention with a reasonable expectation of success. The ordinary artisan would have been motivated to make this combination because Soumillon specifically teaches that all of the claimed components can be used in their nanopen array and Correa teaches assays related to these components. In addition, one having ordinary skill in the art would have recognized that the known techniques in the cited references could have been combined with predictable results because the known techniques in the cited references predictably result in the monitoring of cellular assays by sequencing techniques. 7. Claims 36-38 are rejected under 35 U.S.C. 103 as being unpatentable over Soumillon et al (International Patent Application No. WO 2018064640, published 05 April 2018) in view of Schimak et al (MiL-FISH: Multilabeled Oligonucleotides for Fluorescence In Situ Hybridization Improve Visualization of Bacterial Cells, Applied Environmental Microbiology, 82, 1, published 22 December 2015) as applied to claims 27 and 29 above, and further in view of Love et al (United States Patent Application No. US20190218607, published 18 July 2019). Regarding claims 36-38, the methods of claims 27 and 29 are discussed fully above and incorporated here. Soumillon teaches a microfluidic substrate wherein cells and oligonucleotide-conjugated beads are co-partitioned within individual pens (i.e., wells). Soumillon does not teach a gasket that divides the plurality of wells into separated areas nor do they teach a solid support comprising more than 100,000 wells. However, Love teaches a solid support detection system wherein a gasket is used to separate the wells into 6 separate areas (FIG. 18 and [0395]) and that such solid supports comprise 10,000-1,000,000 wells ([0003]). It would have been obvious to one having ordinary skill in the art to have substituted the microfluidic substrate taught by Soumillon with the seq-well substrate taught by Love to arrive at the instantly claimed invention with a reasonable expectation of success. The ordinary artisan would have been motivated to make this substitution because the substrate taught by Soumillon only teaches up to a maximum of 20,000 pens ([00377]) and the device taught by Love would allow for the analysis of many more single cell samples per experiment. In addition, one having ordinary skill in the art would have recognized that the known techniques in the cited references could have been combined with predictably results because the known techniques in the cited reference predictably result in the co-partitioning of cells with barcoded beads in reaction wells as a precursor to single-cell library preparation and sequencing. 8. Claim 66 is rejected under 35 U.S.C. 103 as being unpatentable over Soumillon et al (International Patent Application No. WO 2018064640, published 05 April 2018) in view of Schimak et al (MiL-FISH: Multilabeled Oligonucleotides for Fluorescence In Situ Hybridization Improve Visualization of Bacterial Cells, Applied Environmental Microbiology, 82, 1, published 22 December 2015) as applied to claim 27 above, and further in view of Kokoris et al (United States Patent Application No. US 20170037456, published 09 February 2017). Regarding claim 66, the solid support detection system of claim 27 is discussed fully above and incorporated here. Neither Soumillon nor Schimak teach that the oligonucleotide complex is attached to the bead via a reversible linker. However, Kokoris teaches DNA complexes comprising capture probes attached to beads via a reversible linker ([0049]). It would have been obvious to one having ordinary skill in the art to have modified the oligonucleotide complex taught by Soumillon in view of Schimak to have comprised a reversible linker as taught by Kokoris to arrive at the instantly claimed invention with a reasonable expectation of success. The ordinary artisan would have been motivated to make this modification in order to cleave the oligonucleotide complex from the bead for more efficient retrieval of captured nucleic acids for downstream application. In addition, one having ordinary skill in the art would have recognized that the known techniques in the cited references could have been combined with predictable results because the known techniques in the cited references predictably result in the attachment of oligonucleotide species to beads. 9. Claim 67 is rejected under 35 U.S.C. 103 as being unpatentable over Soumillon et al (International Patent Application No. WO 2018064640, published 05 April 2018) in view of Schimak et al (MiL-FISH: Multilabeled Oligonucleotides for Fluorescence In Situ Hybridization Improve Visualization of Bacterial Cells, Applied Environmental Microbiology, 82, 1, published 22 December 2015) as applied to claim 27 above, and further in view of Eltoukhy et al (United States Patent Application US 20150266022, published 24 September 2015). Regarding claim 67, the solid support detection system of claim 27 is discussed fully above and incorporated here. Neither Soumillon nor Schimak teach that the solid support comprises a fiber optic faceplate, wherein each fiber of the faceplate is aligned with one of the plurality of wells. However, Eltoukhy teaches a substrate that comprises a fiber optic faceplate, wherein optical fibers are aligned with wells to facilitate subsequent analysis ([0144] and FIGs 11 and 12). It would have been obvious to have modified the substrate taught by Soumillon in view of Schimak to have incorporated the fiber-optic faceplate as taught by Eltoukhy to arrive at the instantly claimed invention with a reasonable expectation of success. The ordinary artisan would have been motivated to make such a modification because Soumillon teaches a CCD based detection ([00389]) and Eltoukhy teaches that fiber-optic detectors are known alternates to CCD detectors ([0144] and [0145]). In addition, one having ordinary skill in the art would have recognized that the known techniques in the cited references could have been combined with predictable results because the known techniques in the cited references predictably result in the detection and analysis of signals from wells. Double Patenting 10. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. 11. Claims 19, 24-27, 29-32, 34-35 and 68 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 19-26 of copending Application No. 19/028,385 in view of Soumillon et al (International Patent Application No. WO 2018064640, published 05 April 2018) and Schimak et al (MiL-FISH: Multilabeled Oligonucleotides for Fluorescence In Situ Hybridization Improve Visualization of Bacterial Cells, Applied Environmental Microbiology, 82, 1, published 22 December 2015). Claim 19 of the copending application teaches all the limitations of instant claim 27 except the limitations that at least one nucleotide sequence of the second plurality of nucleotide sequences carries two or more distinct fluorescent labels, wherein the second plurality of nucleotide sequences is capable of forming a number of uniquely distinguishable fluorescent combinations that exceeds the number of distinct fluorescent labels used to form each fluorescent word. However, Soumillon in view of Schimak teaches these limitations as discussed fully above and incorporated here. It would have been obvious to one having ordinary skill in the art to have modified the hybridization probes in the copending claims with the combinatorially labeled probes taught by Schimak to arrive at the instantly claimed invention with a reasonable expectation of success. The ordinary artisan would have been motivated to make this modification because Schimak specifically teaches that multi-labeled probes provide a higher maximum signal and an increased signal to background as compared to single-labeled probes (pg. 66 column 2 ¶ 2), providing potential advantages such as time saving through reduced exposure times or increased accuracy of barcode assignment. In addition, one having ordinary skill in the art would have recognized that the known techniques in the cited references could have been combined with predictable results because the known techniques in the cited references predictably result in the spatial imaging of fluorescent oligonucleotide probes. The limitations of claims 28 and 29 of the instant application are taught by claims 19 and 24 of the copending application. The limitations of claims 30-32, 34 and 35 and 68 are by claim 19 of the copending application in view of Soumillon. This is a provisional nonstatutory double patenting rejection. Claims 20-23 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 19-26 of copending Application No. 19/028,385 in view of Soumillon et al (international Patent Application No. WO2018064640, published 05 April 2018) and Schimak et al (MiL-FISH: Multilabeled Oligonucleotides for Fluorescence In Situ Hybridization Improve Visualization of Bacterial Cells, Applied Environmental Microbiology, 82, 1, published 22 December 2015) as applied to claim 27 above, and further in view of Cekan et al (International Patent Application No. WO 2020070325, with valid priority to 05 October 2018). Neither the copending application, Soumillon nor Schimak teach the limitations of claim 33. However, Cekan teaches these limitations as discussed fully above and incorporated here. It would have been obvious to one having ordinary skill in the art to have modified the optically readable probe taught by the copending application in view of Soumillon and Schimak to have incorporated up to at least 8 fluorophores, as specifically taught by Schimak (pg. 66 column 2 ¶ 3), and to have at least 7 of those fluorophores be spectrally distinct fluorophores as taught by Cekan, to arrive at the instantly claimed invention with a reasonable expectation of success. The ordinary artisan would have been motivated to increase the number of distinct fluorophores in order to combinatorially increase the number of possible targets (i.e., words) as taught by Schimak (e.g., at 7 distinct fluorophores as disclosed by Cekan, Schimak teaches that there are 2n-1 possible targets, or 127 possible words). In addition, the ordinary artisan would have recognized that the known techniques in the cited references could have been combined with predictable results because the known techniques in the cited references predictably result in the imaging of multiply-labeled oligonucleotide probes. This is a provisional nonstatutory double patenting rejection. Claim 33 is provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 19-26 of copending Application No. 19/028,385 in view of Soumillon et al (international Patent Application No. WO2018064640, published 05 April 2018) and Schimak et al (MiL-FISH: Multilabeled Oligonucleotides for Fluorescence In Situ Hybridization Improve Visualization of Bacterial Cells, Applied Environmental Microbiology, 82, 1, published 22 December 2015) as applied to claim 31 above, and further in view of Correa et al (Evaluation of antigen-conjugated fluorescent beads to identify antigen-specific B cells, Frontiers in Immunology, 9, 493, 1-17, published 23 March 2018). Neither the copending application, Soumillon nor Schimak teach the limitations of claim 33. However, Correa teaches these limitations as discussed fully above and incorporated here. It would have been obvious to one having ordinary skill in the art to have modified the copending claims in view of the methods taught by Soumillon in view of Schimak such that antigen-coated beads were sequestered with B-cells as taught by Correa to arrive at the instantly claimed invention with a reasonable expectation of success. The ordinary artisan would have been motivated to make this combination because Soumillon specifically teaches that all of the claimed components can be used in their nanopen array and Correa teaches assays related to these components. In addition, one having ordinary skill in the art would have recognized that the known techniques in the cited references could have been combined with predictable results because the known techniques in the cited references predictably result in the monitoring of cellular assays by sequencing techniques. This is a provisional nonstatutory double patenting rejection. Claims 36-38 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 19-26 of copending Application No. 19/028,385 in view of Soumillon et al (International Patent Application No. WO2018064640, published 05 April 2018) and Schimak et al (MiL-FISH: Multilabeled Oligonucleotides for Fluorescence In Situ Hybridization Improve Visualization of Bacterial Cells, Applied Environmental Microbiology, 82, 1, published 22 December 2015) as applied to claims 27 and 29 above, and further in view of Love et al (United States Patent Application No. US20190218607, published 18 July 2019). Neither the copending application, Soumillon nor Schimak teach the limitations of claims 35-38. However, Love teaches these limitations as discussed fully above and incorporated here. It would have been obvious to one having ordinary skill in the art to have substituted the microfluidic substrate taught by the copending application in view of Soumillon and Schimak with the seq-well substrate taught by Love to arrive at the instantly claimed invention with a reasonable expectation of success. The ordinary artisan would have been motivated to make this substitution because the substrate taught by Soumillon only teaches up to a maximum of 20,000 pens ([00377]) and the device taught by Love would allow for the analysis of many more single cell samples per experiment. In addition, one having ordinary skill in the art would have recognized that the known techniques in the cited references could have been combined with predictably results because the known techniques in the cited reference predictably result in the co-partitioning of cells with barcoded beads in reaction wells as a precursor to single-cell library preparation and sequencing. This is a provisional nonstatutory double patenting rejection. Claim 66 is provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 19-26 of copending Application No. 19/028,385 in view of Soumillon et al (International Patent Application No. WO2018064640, published 05 April 2018) and Schimak et al (MiL-FISH: Multilabeled Oligonucleotides for Fluorescence In Situ Hybridization Improve Visualization of Bacterial Cells, Applied Environmental Microbiology, 82, 1, published 22 December 2015) as applied to claim 27 above, and further in view of Kokoris et al (United States Patent Application No. US 20170037456, published 09 February 2017). Neither the copending application, Soumillon nor Schimak teach the limitations of claim 66. However, Kokoris teaches these limitations as discussed fully above and incorporated here. It would have been obvious to one having ordinary skill in the art to have substituted the microfluidic substrate taught by the copending application in view of Soumillon and Schimak with the to have comprised a reversible linker as taught by Kokoris to arrive at the instantly claimed invention with a reasonable expectation of success. The ordinary artisan would have been motivated to make this modification in order to cleave the oligonucleotide complex from the bead for more efficient retrieval of captured nucleic acids for downstream application. In addition, one having ordinary skill in the art would have recognized that the known techniques in the cited references could have been combined with predictable results because the known techniques in the cited references predictably result in the attachment of oligonucleotide species to beads. This is a provisional nonstatutory double patenting rejection. Claim 67 is provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 19-26 of copending Application No. 19/028,385 in view of Soumillon et al (International Patent Application No. WO2018064640, published 05 April 2018) and Schimak et al (MiL-FISH: Multilabeled Oligonucleotides for Fluorescence In Situ Hybridization Improve Visualization of Bacterial Cells, Applied Environmental Microbiology, 82, 1, published 22 December 2015) as applied to claim 27 above, and further in view of Eltoukhy et al (United States Patent Application US 20150266022, published 24 September 2015). Neither the copending application, Soumillon nor Schimak teach the limitations of claim 67. However, Eltoukhy teaches these limitations as discussed fully above and incorporated here. It would have been obvious to one having ordinary skill in the art to have substituted the microfluidic substrate taught by the copending application in view of Soumillon and Schimak to have incorporated the fiber-optic faceplate as taught by Eltoukhy to arrive at the instantly claimed invention with a reasonable expectation of success. The ordinary artisan would have been motivated to make such a modification because Soumillon teaches a CCD based detection ([00389]) and Eltoukhy teaches that fiber-optic detectors are known alternates to CCD detectors ([0144] and [0145]). In addition, one having ordinary skill in the art would have recognized that the known techniques in the cited references could have been combined with predictable results because the known techniques in the cited references predictably result in the detection and analysis of signals from wells. This is a provisional nonstatutory double patenting rejection. Response to Arguments 12. Any rejection in the Office Action filed 06 April 2026 not reiterated here has been overcome by amendments to the claims. Applicant’s arguments with respect to claims 27 and 29-38 have been considered but are moot because the new ground of rejection does not rely on any reference applied in the prior rejection of record for any teaching or matter specifically challenged in the argument. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Conclusion 13. No claims are allowed. 14. Any inquiry concerning this communication or earlier communications from the examiner should be directed to BRIAN ELLIS YOUNG whose telephone number is (703)756-5397. The examiner can normally be reached M-T 0800 - 1630. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Heather Calamita can be reached at (571) 272-2876. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /BRIAN ELLIS YOUNG/Examiner, Art Unit 1684 /JULIET C SWITZER/Primary Examiner, Art Unit 1682
Read full office action

Prosecution Timeline

Mar 02, 2022
Application Filed
Apr 06, 2026
Non-Final Rejection mailed — §103, §DOUBLEPATENT
Aug 04, 2026
Response Filed
Oct 30, 2026
Final Rejection mailed — §103, §DOUBLEPATENT (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12747475
COMPOSITIONS AND METHODS OF MAKING GENE EXPRESSION LIBRARIES
2y 11m to grant Granted Sep 29, 2026
Patent 12742194
METHODS AND COMPOSITIONS FOR HIGH THROUGHPUT SAMPLE PREPARATION USING DOUBLE UNIQUE DUAL INDEXING
4y 8m to grant Granted Sep 22, 2026
Patent 12735743
RESOLVING SPATIAL ARRAYS
5y 6m to grant Granted Sep 15, 2026
Patent 12723245
METHODS AND COMPOSITIONS FOR PHASED SEQUENCING
4y 7m to grant Granted Sep 01, 2026
Patent 12680097
METHODS FOR INCREASING YIELD OF SEQUENCING LIBRARIES
5y 1m to grant Granted Jul 14, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
65%
Grant Probability
86%
With Interview (+21.4%)
3y 9m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 40 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month